TD Cowen Initiates Coverage On Nektar Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 52.0%

Neg 0% Neu 52% Pos 0%

TD Cowen analyst Marc Frahm initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating.

Comments

No comments yet. Be the first!